December 11, 2025 – Zug, Switzerland: As part of its ongoing commitment to Corporate Social Responsibility (CSR), RGCC International is proud to announce a donation of €15,000 to the Department of Pediatric Oncology and Hematology at Charité – Universitätsmedizin Berlin. The contribution will directly support the hospital’s pioneering CAR-T Cell Therapy research program, which is dedicated to advancing innovative immunotherapies for children battling cancer.
Funds from this donation will assist the Charité team in accelerating their research on CAR-T cell therapy for leukemia and other pediatric tumors. CAR-T cell therapy is an advanced and highly personalized form of immunotherapy that trains a patient’s own immune system to recognize and destroy cancer cells.
“At RGCC, we are dedicated to supporting groundbreaking scientific and medical initiatives that can make a lasting difference in people’s lives,” said Dr. Ioannis Papasotiriou, Director of RGCC International. “We are honored to contribute to the vital work being carried out at Charité – Universitätsmedizin Berlin. Their commitment to advancing CAR-T cell therapy represents a powerful step forward in improving treatment options and outcomes for children with cancer.”
RGCC International remains committed to its CSR mission and will continue to support organizations and scientific programs that contribute to the health and well-being of communities worldwide.
About RGCC International:
RGCC was launched in 2004 by genetics pioneer Dr. Ioannis Papasotiriou who believes that the key to effectively treating cancer lies in personalized medicine. Today, RGCC is a leading innovator in the field of oncology diagnostics. Using world-leading technology, equipment, and innovative techniques, our team of scientists has developed a range of liquid biopsies that help physicians track cancer progression and tailor treatment plans based on individual patient profiles.
For more info visit: rgcc-international.com